Lymphoma (includes NHL, HL, CNS Lymphoma)

FDA Approves RITUXAN HYCELA (Rituximab and Hyaluronidase Human) for Subcutaneous Injection in Certain Blood Cancers

(Genentech) June 22, 2017 - Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) approved RITUXAN HYCELA™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukemia (CLL).

read corporate press release

FDA Approves Rituximab Plus Hyaluronidase Combination for Treatment of FL, DLBCL and CLL

(ASCO in Action) June 22, 2017 - On June 22, 2017, the U.S. Food and Drug Administration granted regular approval to the combination of rituximab and hyaluronidase human (RITUXAN HYCELA, Genentech Inc.) for adult patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.

read article

Roche Presents New Data From GALLIUM Study Reinforcing Clinical Benefit of Gazyva/Gazyvaro in People With Previously Untreated Follicular Lymphoma

(Roche) June 23, 2017 - Roche announced today that new data from additional analyses of the pivotal phase III GALLIUM study in people with previously untreated follicular lymphoma will be presented at the 22nd European Hematology Association (EHA) annual congress, 22-25 June, in Madrid, Spain.

read corporate press release

Karyopharm Reports Updated Phase 2b SADAL Data for Selinexor in Diffuse Large B-Cell Lymphoma at the 2017 European Hematology Association Annual Meeting

(Morningstar) June 23, 2017 - Karyopharm Therapeutics Inc. today reported updated clinical data from the ongoing Phase 2b Selinexor Against Diffuse Aggressive Lymphoma (SADAL) study evaluating lead product candidate, selinexor (KPT-330), an oral Selective Inhibitor of Nuclear Export / SINE™ compound, in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

read article

Spectrum Pharmaceuticals Highlights Results of a Combination Study of FOLOTYN® (pralatrexate injection) Plus Romidepsin Presented at the 14th International Conference on Malignant Lymphoma (14-ICML) Meeting

(Yahoo! Finance) June 19, 2017 - The FOLOTYN (antifolate) and an HDAC inhibitor (romidepsin) combination was shown to achieve a 71% overall response rate (ORR) among PTCL patients.

read article

Novartis’ MabThera Biosimilar Wins EU Nod

(PharmaTimes [UK]) June 19, 2017 - Novartis is poised to turn up the pressure on sales of Roche’s monoclonal antibody MabThera/Rituxan after EU regulators approved its cheaper biosimilar version of the mega blockbuster for use across blood malignancies and immunological diseases.

read article

Novartis Secures European Approval For Biosimilar Cancer Treatment Rixathon

(TheStreet) June 19, 2017 - Novartis AG said Monday that it has received approval from the European Commission for a blood cancer treatment known as Rixathon, a biosimilar version of Roche AG's blockbuster Rituxan that generated around $7.5 billion in sales last year.

read article

NHS Future ‘Uncertain’ for Adcetris in ALCL

(PharmaTimes [UK]) June 19, 2017 - Cost regulators for NHS treatments in England and Wales say they are currently minded not to recommend Takeda’s Adcetris on the NHS for relapsed or refractory systemic anaplastic large cell lymphoma (ALCL), a cancer of the lymphatic system.

read article

Juno Therapeutics Presents TRANSCEND NHL 001 Trial Data at International Conference on Malignant Lymphoma

(Biotech 365) June 17, 2017 - Juno Therapeutics, Inc., a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today presented data from the TRANSCEND trial of JCAR017 in relapsed and refractory (r/r) aggressive B cell non-Hodgkin lymphoma (NHL) at the 2017 International Conference on Malignant Lymphoma in Lugano, Switzerland.

read article

Updated Data from Phase IIIb MAGNIFY Study of REVLIMID (lenalidomide) and Rituximab Combination (R2) Show Clinical Activity and Responses in Relapsed/Refractory Follicular and Marginal Zone Lymphoma

(Celgene) June 17, 2017 - Celgene Corporation today announced results from an interim analysis of MAGNIFY, a phase IIIb, randomized, open-label, multicenter study of REVLIMID (lenalidomide) plus rituximab (R2) combination therapy in patients with relapsed or refractory marginal zone lymphoma (MZL). Results were presented at the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland and expanded upon data presented earlier in the month at the American Society of Clinical Oncology (ASCO) meeting in Chicago, Ill.

read corporate press release

Extended Follow-Up Data Evaluating Opdivo (nivolumab) Shows Durable Response in Adult Patients with Relapsed or Progressed Classical Hodgkin Lymphoma

(BMS) June 16, 2017 - Bristol-Myers Squibb Company today announced extended follow-up data in which Opdivo (nivolumab) demonstrated responses in adult patients with relapsed or progressed classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT), irrespective of brentuximab vedotin (BV) therapy history.

read corporate press release

After a Sharp Plunge, Epizyme Bounces Back On Some Bonny Forecasts As Shares Go On A Roller Coaster Ride

(Endpoints News) June 15, 2017 - Yesterday I reported that Epizyme shares took a dive after the company reported some disappointing data on its DLBCL group in an ongoing Phase II study of tazemetostat.

read article

In Lymphoma, Best Partner With Rituximab Still in Question

(Medscape Medical News) June 15, 2017 - Results from the long-term follow-up of frontline therapy for patients with indolent non-Hodgkin's lymphoma (iNHL) show the long-term benefits of chemotherapy in combination with rituximab (Rituxan, Roche/Genentech).

read article (free registration required)

Final NICE Nod For Takeda’s Adcetris in Hodgkin’s Lymphoma

(PharmaTimes [UK]) June 15, 2017 - Certain patients with Hodgkin’s Lymphoma living in England and Wales can now expect routine access to Takeda’s Adcetris on the NHS after NICE deemed the drug a cost-effective use of resources in some scenarios.

read article

GW Cancer Center Researchers Look at Resistance to Targeted Therapy in Mantle Cell Lymphoma

(GW Cancer Center) June 14, 2017 - Today some patients suffering with mantle cell lymphoma, a type of blood cancer, can be treated with a pill called ibrutinib, forgoing conventional chemotherapy.

read press release

Seattle Genetics and Bristol-Myers Squibb Highlight Interim Phase 1/2 Data Evaluating Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed Hodgkin Lymphoma at the International Conference on Malignant Lymphoma

(BMS) June 15, 2017 - Seattle Genetics, Inc. and Bristol-Myers Squibb Company today highlighted an updated interim analysis from the ongoing phase 1/2 clinical trial evaluating ADCETRIS (brentuximab vedotin) and Opdivo (nivolumab) in relapsed or refractory (RR) classical Hodgkin lymphoma (HL) at the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland.

read corporate press release

Portola Pharmaceuticals Presents Interim Phase 2a Safety and Efficacy Data for Cerdulatinib at the International Congress of Malignant Lymphoma

(Portola) June 15, 2017 - Portola Pharmaceuticals Inc.® today announced the presentation of interim data from a Phase 2a study evaluating cerdulatinib in patients with relapsed/refractory B-cell malignancies.

read corporate press release

Celltrion Healthcare Showcases Data Supporting the Efficacy and Safety of Truxima® (CT-P10, biosimilar rituximab) in Advanced Follicular Lymphoma and Rheumatoid Arthritis

(Yahoo! Finance) June 14, 2017 - New data presented at the International Conference on Malignant Lymphoma (ICML) and the European League Against Rheumatism (EULAR) congress 2017 demonstrate that CT-P10 is comparable to reference rituximab in terms of efficacy and safety in both oncology and autoimmune disease indications.

read article

BeiGene Presents Updated Phase 1 Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the 14th International Conference on Malignant Lymphoma

(BeiGene) June 14, 2017 - BeiGene, Ltd. today presented updated clinical data from an ongoing Phase 1 study of BTK inhibitor BGB-3111 in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in a poster at the 14th International Conference on Malignant Lymphoma (14-ICML) in Lugano, Switzerland.

read corporate press release

Kura Oncology Presents Preliminary Clinical and Preclinical Data for Tipifarnib in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

(NASDAQ) June 14, 2017 - Kura Oncology, Inc., a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that clinical and preclinical data for tipifarnib in the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) was presented at the International Conference on Malignant Lymphoma (ICML) being held June 14-17, 2017 in Lugano, Switzerland.

read article
Next Page